To the best of our knowledge, ours is the only community-based study to validate the usefulness of ddPCR instead of invasive tissue biopsies for detecting mutations in NSCLC patients with acquired resistance to EGFR-TKI. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.